- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06516965
En studie för att utvärdera effektivitets- och säkerhetsstudien av Povorcitinib hos deltagare med Prurigo Nodularis (STOP-PN2)
En fas 3, randomiserad, dubbelblind, placebokontrollerad, effekt och säkerhetsstudie av Povorcitinib hos deltagare med Prurigo Nodularis
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Fremantle, Australien, 06160
- Fremantle Dermatology
-
-
New South Wales
-
Charlestown, New South Wales, Australien, 02290
- Novatrials
-
Kogarah, New South Wales, Australien, 02217
- Premier Specialists Pty Ltd
-
Sydney, New South Wales, Australien, 02010
- Skin & Cancer Foundation Australia
-
Westmead, New South Wales, Australien, 02145
- Westmead Hospital
-
-
Queensland
-
Woolloongabba, Queensland, Australien, 04102
- Veracity Clinical Research Pty Ltd
-
-
Victoria
-
Melbourne, Victoria, Australien, 03004
- The Alfred Hospital
-
-
-
-
-
Bruges, Belgien, 08000
- Az Sint-Jan Brugge Av
-
Ghent, Belgien, 09000
- Universitair Ziekenhuis Gent (Uz Gent)
-
Gilly, Belgien, 06060
- Grand Hopital de Charleroi - Site Imtr
-
Liège, Belgien, 04000
- Centre Hospitalier Universitaire (Chu) de Liege - Domaine Universitaire Du Sart Tilman
-
Woluwe-Saint-Lambert, Belgien, 01200
- Universite Catholique de Louvain (Ucl) - Cliniques Universitaires Saint-Luc
-
-
-
-
-
Santiago, Chile, 7580206
- Centro Medico Skinmed Limitada
-
Santiago, Chile, 8420383
- Centro Internacional de Estudios Clinicos
-
Valdivia, Chile, 5090000
- Clinical Research Chile Spa.
-
-
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85006
- Medical Dermatology Specialists Phoenix
-
Scottsdale, Arizona, Förenta staterna, 85255
- Investigate Md
-
-
California
-
Fountain Valley, California, Förenta staterna, 92708-3701
- First Oc Dermatology Research Inc
-
Santa Monica, California, Förenta staterna, 90404
- Clinical Science Institute Clinical Research Specialists Inc
-
-
Florida
-
Aventura, Florida, Förenta staterna, 33180
- Center For Clinical and Cosmetic Research
-
Boca Raton, Florida, Förenta staterna, 33428
- Schweiger Dermatology
-
Hialeah, Florida, Förenta staterna, 33012
- Direct Helpers Research Center
-
Hollywood, Florida, Förenta staterna, 33201
- Skin Care Research, Llc
-
Miami, Florida, Förenta staterna, 33162
- Ziaderm Research, Llc
-
Tampa, Florida, Förenta staterna, 33609
- Trueblue Clinical Research Moore Clinical Research, Inc McR Tampa Clinic Location
-
Tampa, Florida, Förenta staterna, 33607
- Nodal Medical Center, Llc
-
-
Kentucky
-
Louisville, Kentucky, Förenta staterna, 40241
- Dermatology Specialists Research
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21201
- University of Maryland School of Medicine
-
Rockville, Maryland, Förenta staterna, 20850
- Dermatology Associates Pc
-
-
Massachusetts
-
Brighton, Massachusetts, Förenta staterna, 02135-3511
- Metro Boston Clinical Partners
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48103
- Fivenson Dermatology
-
Detroit, Michigan, Förenta staterna, 48202
- Henry Ford Health System
-
Waterford, Michigan, Förenta staterna, 48328
- Michigan Dermatology Institute
-
-
New Hampshire
-
Portsmouth, New Hampshire, Förenta staterna, 03801
- Allcutis Research, Llc
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna, 07601
- Schweiger Dermatology
-
-
New York
-
New York, New York, Förenta staterna, 10128
- OPTISKIN
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45267
- University of Cincinnati Cancer Institute
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73118
- Central Sooner Research
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19103
- Paddington Testing Co Inc
-
Yardley, Pennsylvania, Förenta staterna, 19067
- Yardley Dermatology Associates
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75231
- Modern Research Associates Pllc
-
-
Utah
-
Murray, Utah, Förenta staterna, 84107
- University of Utah Midvalley Dermatology
-
-
Washington
-
Burien, Washington, Förenta staterna, 98168
- Aesthetic General Dermatology of Seattle
-
-
-
-
-
Bunkyō City, Japan, 113-8519
- Tokyo Medical and Dental University Hospital, Faculty of Medicine
-
Inashiki-gun, Japan
- Tokyo Medical University Ibaraki Medical Center - Kasumigaura Campus (Tokyo Medical University Kasum
-
Kamimashiki-gun, Japan, 861-3101
- Noguchi Dermatology Clinic
-
Kawasaki-shi, Japan, 211-8533
- Nippon Medical School Musashikosugi Hospital
-
Kitakyushu, Japan, 807-8555
- University of Occupational and Environmental Health, Japan
-
Kobe, Japan, 657-0846
- Shimizu Dermatology Clinic
-
Kumamoto, Japan, 861-2236
- Aoi Dermatology Clinic
-
Minamikoshigaya, Japan, 343-8555
- Dokkyo Medical University Saitama Medical Center
-
Minokamo, Japan, 505-8510
- Central Japan International Medical Center
-
Niigata, Japan, 951-8520
- Niigata University Medical & Dental Hospital
-
Osaka, Japan, 558-0003
- Medical Corporation Jun Dermatology Clinic
-
Sakai, Japan, 593-8324
- Kume Derma Clinic
-
Sapporo, Japan, 600063
- Sapporo Skin Clinic
-
Sendai, Japan, 980-8574
- Tohoku University Hospital
-
Shinjuku-ku, Japan, 160-0023
- Tokyo Medical University Hospital
-
Tokorozawa, Japan, 359-0042
- National Defense Medical College Hospital
-
Yokohama, Japan, 221-0825
- Nomura Dermatology Clinic
-
Yokohama, Japan, 220-6208
- Queen'S Square Medical Facilities
-
Ōta-ku, Japan, 143-0023
- Tanpopo Dermatology Clinic
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6W 4V4
- Skin Physicians
-
Edmonton, Alberta, Kanada, T6X 0N9
- Alpha Research-Lucere Dermatology and Laser Clinic
-
-
Ontario
-
Barrie, Ontario, Kanada, L4M 7G1
- Simcoderm Medical and Surgical Dermatology Centre
-
London, Ontario, Kanada, N6H 5L5
- Dermeffects
-
Toronto, Ontario, Kanada, M2N 3A6
- North York Research Inc.
-
Toronto, Ontario, Kanada, M3H 5Y8
- Toronto Research Centre
-
-
Quebec
-
Québec, Quebec, Kanada, G1W 4R4
- Centre de Recherche Saint-Louis
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Kanada, S7K 2C1
- Skinsense Medical Research
-
-
-
-
-
Gdansk, Polen, 80-280
- Akk Medical Sp. Z O.O. - Centrum Medyczne Tu Sie Leczy
-
Katowice, Polen, 40-568
- Care Clinic Sp. Z O.O.
-
Lodz, Polen, 90-436
- Dermoklinika Centrum Medyczne S.C., M. Kierstan, J. Narbutt, A. Lesiak
-
Lodz, Polen, 90-302
- Santa Familia Ptg Lodz
-
Lublin, Polen, 20-573
- Luxderm Specjalistyczny Gabinet Dermatologiczny Prof. Dr. Hab. N. Med. Dorota Krasowska
-
Poznan, Polen, 61-731
- Clinical Research Center Spolka Z Ograniczona Odpowiedzialnoscia Medic-R Spolka Komandytowa
-
Rzeszów, Polen, 35-055
- Uniwersytecki Szpital Kliniczny Im. Fryderyka Chopina W Rzeszowie
-
Torun, Polen, 87-100
- Mics Centrum Medyczne Torun
-
Warsaw, Polen, 02-692
- Royalderm Agnieszka Nawrocka
-
Warsaw, Polen, 01-817
- High-Med. Przychodnia Specjalistyczna
-
Warsaw, Polen, 02-507
- Panstwowy Instytut Medyczny Mswia
-
Wroclaw, Polen, 50566
- Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spolka Partnerska
-
-
-
-
-
Alicante, Spanien, 03010
- Hospital General Universitario Dr Balmis
-
Badalona, Spanien, 08916
- Hospital Universitari Germans Trias I Pujol (Hugtp)
-
Barcelona, Spanien, 08041
- Hospital de La Santa Creu I Sant Pau
-
Córdoba, Spanien, 14004
- Hospital Universitario Reina Sofia
-
Granada, Spanien, 18016
- Hospital Clinico Universitario San Cecilio
-
Madrid, Spanien, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spanien, 28046
- Hospital Universitario La Paz
-
Madrid, Spanien, 28034
- Hospital Universitario Ramon Y Cajal
-
Majadahonda, Spanien, 28222
- Hospital Universitario Puerta de Hierro de Majadahonda
-
Manises, Spanien, 46940
- Hospital de Manises
-
Santiago de Compostela, Spanien, 15706
- Area Sanitaria de Santiago de Compostela Y Barbanza - Complejo Hospitalario Universitario de Santiag
-
Seville, Spanien, 41013
- Hospital Universitario Virgen Del Rocio
-
Valencia, Spanien, 46026
- Universitat de Valencia - Hospital Universitari I Politecnic La Fe de Valencia (Hospital La Fe Bulev
-
-
-
-
-
Dudley, Storbritannien, DY1 2HQ
- The Dudley Group Nhs Foundation Trust
-
Ipswich, Storbritannien, IP4 5PD
- Ipswich Hospital, East Suffolk and North Essex Nhs Foundation Trust
-
Liverpool, Storbritannien, L14 3LB
- Broadgreen Hospital - Liverpool University Hospitals Nhs Foundation Trust
-
London, Storbritannien, SE1 9RT
- Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust
-
London, Storbritannien, E1 1FR
- The Royal London Hospital - Barts Health Nhs Trust
-
Poole, Storbritannien, BH15 2JB
- Poole Hospital - University Hospitals Dorset Nhs Foundation Trust
-
Redhill, Storbritannien
- Surrey and Sussex Healthcare Nhs Trust - East Surrey Hospital
-
-
-
-
-
Prague, Tjeckien, 158 00
- Sanixtra Prague
-
Prague, Tjeckien, 100 00
- Clintrial S.R.O.
-
Prague, Tjeckien, 110 00
- Sanatorium Profesora Arenbergera
-
-
-
-
-
Aachen, Tyskland, 52074
- University Hospital Rwth Aachen
-
Buxtehude, Tyskland, 21614
- Elbe Kliniken Buxtehude
-
Chemnitz, Tyskland, 09117
- Drk Krankenhaus Chemnitz-Rabenstein
-
Darmstadt, Tyskland, 64283
- Klinikum Darmstadt
-
Darmstadt, Tyskland, 64283
- Rosenpark Research Gmbh
-
Dresden, Tyskland, 01307
- University Hospital Carl Gustav Carus
-
Frankfurt am Main, Tyskland, 60590
- Klinikum Der Johann Wolfgang Goethe-Universitaet
-
Göttingen, Tyskland, 37075
- Universitaetsmedizin Goettingen
-
Magdeburg, Tyskland, 39104
- Magdeburger Company For Medical Studies and Services Gmbh
-
Mainz, Tyskland, 55128
- Dermatologische Gemeinschaftspraxis Dres. Quist
-
München, Tyskland, 80802
- Technischen Universitaet Muenchen
-
Münster, Tyskland, 48149
- University Hospital Muenster
-
Oldenburg, Tyskland, 26133
- Klinikum Oldenburg Aor
-
Witten, Tyskland, 58453
- Hautarztpraxis Dr. Hoffmann
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male and female participants 18 to 75 years of age.
- Clinical diagnosis of PN for at least 3 months prior to Screening visit.
- Pruritus, defined as an average Itch NRS score ≥ 7 during the 7 days prior to Day 1/Baseline.
- Total of ≥ 20 pruriginous lesions on ≥ 2 different body regions (both legs, and/or both arms, and/or trunk) at Screening and Day 1/Baseline.
- Documented history of treatment failure, demonstrated intolerance, or contraindication to a previous PN treatment.
- Willingness to avoid pregnancy or fathering children.
Exclusion Criteria:
- Chronic pruritus due to a condition other than PN or neuropathic and psychogenic pruritus.
- Diagnosis of PN secondary to medications.
- Active AD lesions (signs and symptoms other than dry skin) within 3 months prior to Screening visit.
- Women who are pregnant (or are considering pregnancy) or breastfeeding.
- Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.
- Evidence of infection with TB, HBV, HCV or HIV.
- History of failure to any topical or systemic JAK or TYK2 inhibitor as treatment of PN or any inflammatory disease.
- Laboratory values outside of the protocol-defined ranges.
Other protocol-defined Inclusion/Exclusion Criteria apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Povorcitinib Dose 1
Povorcitinib at the protocol-defined dose. |
Oral Tablet
Andra namn:
|
|
Experimentell: Povorcitinib Dose 2
Povorcitinib at the protocol-defined dose. |
Oral Tablet
Andra namn:
|
|
Placebo-jämförare: Placebo
Placebo at the protocol-defined dose. |
Oral Tablet |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24
Tidsram: Week 24
|
Defined as proportion of participants achieving a ≥ 4-point improvement [reduction] in Itch NRS score from baseline (Itch NRS4) and an IGA CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline (IGA-CPG-S-TS). |
Week 24
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of participants achieving Itch NRS4 at Week 24
Tidsram: Week 24
|
Defined as percentage of participants that achieve a ≥ 4-point improvement (reduction) in Itch NRS score from baseline. |
Week 24
|
|
Proportion of participants achieving IGA-CPG-S-TS at Week 24
Tidsram: Week 24
|
Defined as percentage of participants that achieve IGA-CPG-S score of 0 or 1 with a ≥ 2 grade improvement from baseline. |
Week 24
|
|
Proportion of participants achieving Itch NRS4 at Week 4
Tidsram: Week 4
|
Defined as percentage of participants that achieve a ≥ 4-point improvement (reduction) in Itch NRS score from baseline. |
Week 4
|
|
Time to Itch NRS4
Tidsram: Up to 52 Weeks
|
Defined as time taken for the participant to achieve a ≥4 improvement in Itch NRS score from baseline. |
Up to 52 Weeks
|
|
Change from baseline in Itch NRS score at each postbaseline visit
Tidsram: Up to 52 weeks
|
Itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". |
Up to 52 weeks
|
|
Percent change from baseline in NRS score at each postbaseline visit
Tidsram: Up to 52 weeks
|
Itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". |
Up to 52 weeks
|
|
Proportion of participants achieving Itch NRS4 at each postbaseline visit
Tidsram: Up to 52 weeks
|
Defined as percentage of participants that achieve a ≥ 4-point improvement in Itch NRS score from baseline. |
Up to 52 weeks
|
|
Proportion of participants achieving IGA-CPG-S-TS at each postbaseline visit
Tidsram: Up to 52 weeks
|
Defined as percentage of participants that achieve an IGA-CPG-S score of 0 or 1 with a ≥ 2 grade improvement from baseline. |
Up to 52 weeks
|
|
Proportion of participants achieving Investigator's Global Assessment - Chronic Prurigo Activity (IGA-CPG-A) at each postbaseline visit
Tidsram: Up to 52 weeks
|
Defined as percentage of participants that achieve an IGA-CPG-A score of 0 or 1 with a ≥ 2 grade improvement (reduction) from baseline. |
Up to 52 weeks
|
|
Proportion of participants achieving ≥ 75% healed lesions in Prurigo Activity Score (PAS) at each postbaseline visit
Tidsram: Up to 52 weeks
|
The modified PAS will be used in this study as defined by the protocol. |
Up to 52 weeks
|
|
Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at each postbaseline visit
Tidsram: Up to 52 weeks
|
Defined as percentage of participants that achieve a ≥ 4-point improvement (reduction) in Itch NRS score and IGA-CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline. |
Up to 52 weeks
|
|
Change from baseline in Dermatology Life Quality Index (DLQI) score at each postbaseline visit.
Tidsram: Up to 52 weeks
|
The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. |
Up to 52 weeks
|
|
Percent change from baseline in Dermatology Life Quality Index (DLQI) score at each postbaseline visit.
Tidsram: Up to 52 weeks
|
The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. |
Up to 52 weeks
|
|
Proportion of participants with at least a 4-point decrease in DLQI score from baseline at each postbaseline visit for participants with DLQI score ≥ 4 at baseline
Tidsram: Up to 52 weeks
|
Defined as percentage of participants with at least a 4-point decrease in DLQI score from baseline at each postbaseline visit for participants with DLQI score ≥ 4 at baseline. |
Up to 52 weeks
|
|
Change from baseline in Skin Pain NRS score at each postbaseline visit
Tidsram: Up to 52 weeks
|
Skin Pain NRS is an 11-point scale (0 to10) where 0 is "no pain" and 10 is the "worst pain imaginable". |
Up to 52 weeks
|
|
Percent change from baseline in Skin Pain NRS score at each postbaseline visit
Tidsram: Up to 52 weeks
|
Skin Pain NRS is an 11-point scale (0 to10) where 0 is "no pain" and 10 is the "worst pain imaginable". |
Up to 52 weeks
|
|
Change from baseline in the Hospital Anxiety and Depression Scale (HADS) score at each postbasline visit
Tidsram: Up to 52 weeks
|
HADS is a 14-item questionnaire that assesses the levels of anxiety and depression that a participant is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question (responses are scored as 0, 1, 2, or 3). |
Up to 52 weeks
|
|
Percent change from baseline in the HADS score at each postbaseline visit
Tidsram: Up to 52 weeks
|
HADS is a 14-item questionnaire that assesses the levels of anxiety and depression that a participant is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question (responses are scored as 0, 1, 2, or 3). |
Up to 52 weeks
|
|
Change from baseline in EQ-5D-5L score at each postbaseline visit
Tidsram: Up to 52 weeks
|
The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome. |
Up to 52 weeks
|
|
Percent change from baseline in EQ-5D-5L score at each postbaseline visit
Tidsram: Up to 52 weeks
|
The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome. |
Up to 52 weeks
|
|
Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) score at each postbaseline visit
Tidsram: Up to 52 weeks
|
The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. |
Up to 52 weeks
|
|
Percent change in FACIT-F score at each postbaseline visit
Tidsram: Up to 52 weeks
|
The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. |
Up to 52 weeks
|
|
Proportion of participants with at least a ≥ 4-point increase in FACIT-F score at each postbaseline visit for participants with FACIT-F score ≤ 48 at baseline
Tidsram: Up to 52 weeks
|
The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. |
Up to 52 weeks
|
|
Number of Participants with Treatment Emergent Adverse Events (TEAE)
Tidsram: Up to 52 weeks
|
Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug. |
Up to 52 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Incyte Medical Monitor, Incyte Corporation
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- INCB54707-306
- 2024-511881-35-00 (Registeridentifierare: EU CT Number)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Tidsram för IPD-delning
Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Kriterier för IPD Sharing Access
Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .